

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/04129 A1

(51) International Patent Classification⁷: C07F 9/24,
C07H 21/00

(21) International Application Number: PCT/DK00/00375

(22) International Filing Date: 7 July 2000 (07.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 1999 00987 7 July 1999 (07.07.1999) DK

(71) Applicant (for all designated States except US): EXIQON
A/S [DK/DK]; Bygstubben 9, DK-2950 Vedbæk (DK).

(72) Inventor; and

(75) Inventor/Applicant (for US only): FENSHOLDT, Jef
[DK/DK]; Ærtemarken 79, DK-2860 Søborg (DK).

(74) Agent: PLOUGMANN, VINGTOFT & PARTNERS
A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021
Copenhagen K (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SYNTHESIS OF STABLE QUINONE AND PHOTOREACTIVE KETONE PHOSPHORAMIDITE REAGENTS FOR SOLID PHASE SYNTHESIS OF PHOTOREACTIVE-OLIGOMER CONJUGATES

(57) Abstract: Quinone phosphoramidite reagents as well as photoreactive ketone phosphoramidite reagents, such as anthraquinone phosphoramidite reagents and benzophenone phosphoramidite reagents were synthesized and used for the solid phase synthesis of photoreactive-oligonucleotide conjugates. These phosphoramidite reagents are stable, suitable for large-scale synthesis and designed for automated solid phase synthesis of oligomers terminating in a photoreactive moiety.



WO 01/04129 A1

SYNTHESIS OF STABLE QUINONE AND PHOTOREACTIVE KETONE
PHOSPHORAMIDITE REAGENTS FOR SOLID PHASE SYNTHESIS OF
PHOTOREACTIVE-OLIGOMER CONJUGATES

5 FIELD OF THE INVENTION

The present invention relates to the field of stable quinone- and photoreactive ketone phosphoramidite reagents designed for automated solid phase synthesis of oligomers terminating in a photoreactive moiety.

10

BACKGROUND OF THE INVENTION

Attachment of a reporter group or another conjugation to oligonucleotides (ONs) has been the subject of considerable research as the resulting functionalised ONs display great
15 potential as diagnostic or therapeutic agents (S. L. Beaucage, *Comprehensive Natural Products Chemistry* Vol. 7. Ed. E.T. Kool, Editors-in-Chief D. Barton and K. Nakanishi, Pergamon, **1999**, 153-250). For example, ONs linked to anthraquinone (anthraquinone-ONs) and derivatives thereof have been prepared with the purpose of increasing the affinity towards complementary ONs via intercalation as well as for studies of site specific
20 modification, cleavage, and crosslinking of duplex structures (K. Mori *et al.*, *FEBS lett.* **1989**, 249, 213-218; S. M. Gasper and G. B. Schuster, *J. Am. Chem. Soc.* **1997**, 119, 12762-12771; L. G. Puskás *et al.*, *Nucleosides Nucleotides*, **1995**, 14, 967; H. Kang and S. E. Rokita; *Nucleic acids Res.*, **1996**, 24, 3896-3902). Another interesting application of anthraquinone-oligomers is the covalent immobilization of oligomers onto polymeric
25 surfaces. Immobilisation of oligomers on various surfaces (Jacobsen, M.H. and Koch, T. WO 96/31557, **1996**), such as plastic microtiter plates, microchips and micro particles has been achieved by various means and form the basis for a rapidly expanding technology within the field of diagnostic assays and disease screening assays (F. N. Rehman *et al.*, *Nucleic acids Res.*, **1999**, 27, 649-655; P. W. Stevens *et al.*, *Nucleic acids Res.*, **1999**, 27, 1719-1727; G. Ramsay, *Nature Biotechnology*, **1998**, 16, 40-44).
30

Two general methods for covalent attachment of anthraquinone to oligomers by chemical means have previously been developed. The first method comprises coupling of an activated anthraquinone derivative with a pre-synthesized oligomer containing a reactive
35 group such as a free primary amine function. This approach is illustrated by Kang and

Rokita (*Nucleic Acids Res.*, **1996**, 24, 3896-3902) who synthesized 5'-end anthraquinone-oligodeoxynucleotides (ODNs) for the studies of site-specific and photo-induced alkylation of DNA. A dimethyl-anthraquinone-ODN conjugate was synthesized by coupling of the *N*-hydroxysuccinimide ester of 2-(3-propionic acid)-1,4-dimethylantraquinone with 5'-amino hexamethylene linked ODN, obtained by standard automated solid phase synthesis. Anthraquinone-ONs have also been prepared by reaction of ONs containing "amino-linker" modified nucleobases or carbohydrate moieties with activated anthraquinone derivatives (Telser *et al. J. Am. Chem. Soc.* **1989**, 111, 7226-7232; Akira *et al. Bioconjugate Chem.* **1993**, 4, 499-508).

10

The other method comprises converting the anthraquinone into a synthon that can be used for automated solid phase synthesis, e.g. coupling of the anthraquinone to a phosphoramidite reagent. Depending on the availability of the building-block it can be argued that this direct incorporation is the most efficient approach, as the total synthesis of the anthraquinone-oligomers can be performed on an automated synthesizer.

15

Attachment of anthraquinone derivatives to ONs via direct incorporation has been approached by linking the anthraquinone group to the 2'-O position of a 5'-O-DMT (4,4'-dimethoxytrityl), 3'-O-phosphoramidite nucleoside reagents. K. Yamana *et al. (Bioconjugate Chem.* **1996**, 7, 715-720) reported the synthesis of 5'-O-dimethoxytrityl 2'-O-(2-anthraquinonylmethyl)uridine 3'-O-cyanoethyl)-*N,N*-diisopropylphosphoramidite which was used for automated solid phase synthesis of anthraquinone-ONs.

20

De Mesmaeker *et al. (Bioorganic, Medicinal Chem.* **1997**, 7, 1869-1874) described the synthesis of nucleoside dimers containing a 3'-5' amide bond, wherein the nitrogen atom is attached to an anthraquinone molecule through a polymethylene linker. DMT-protection of the 5'-O position and phosphitylation of the 3'-O-position of the dimer afforded a reagent suitable for automated synthesis of anthraquinone-ONs.

25

A non-basic pseudonucleoside bearing an anthraquinone moiety has been prepared by K.-Y., Lin and M. Matteucci (*Nucleic Acids Res.* **1991**, 19, 3111-3114, and US 5.214.136). Starting from 2-chloro anthraquinone and diethanol amine an anthraquinone diol derivative was obtained which was converted into a DMT H-phosphonate reagent which was, subsequently, incorporated multiple times into an ODNs.

30

35

The above mentioned reagents allow incorporation of an anthraquinone functionality at different positions in an oligomer.

A few examples of phosphoramidite reagents not derived from nucleosides, developed
5 exclusively for incorporation of anthraquinone at the 5'-terminus of an oligomer using automated solid phase synthesis have been reported.

K. Mori *et al.* (*FEBS Lett.* **1989**, 249, 213-218) describe the synthesis of anti-HIV active
5'-linked anthraquinone-ODNs wherein an anthraquinone derivative is linked to an
10 oligodeoxynucleotide (ODN) via either an ethylpiperazinyl or a hexamethylene linker. The 5'-linked anthraquinone-ODNs were obtained by coupling of a freshly prepared anthraquinone-ethylpiperazinyl phosphoramidite (obtained in 65% yield) or anthraquinone hexamethylene-linked phosphoramidite to the 5'-end of an ODN sequence using standard automated solid phase synthesis.

15

The anthraquinone-ethylpiperazinyl phosphoramidite reagent has also been described in WO 90/12802. The anthraquinone phosphoramidite was synthesised using the same procedure as described by K. Mori *et al.*: 1-chloroanthraquinone was reacted with 1-(2-hydroxyethyl)piperazine affording 1-(1-(2-hydroxyethyl)piperazinyl)anthraquinone
20 which was phosphitylated by *N,N*-diisopropylphosphoramidochloride in the presence *N,N*-diisopropylethylamine to afford anthraquinone-ethylpiperazinyl phosphoramidite. The anthraquinone phosphoramidite was used without further purification in the automated solid phase synthesis of 5'-linked anthraquinone-ODNs used for attenuation or destruction of mammalian genetic expression or viral activity.

25

S. M. Gasper and G. B. Schuster (*J. Am. Chem. Soc.* **1997**, 119, 12762-12771) described the synthesis of 5'-linked anthraquinone-ODNs with the purpose of establishing the fact that oxidative damage can migrate in double-stranded DNA. For this purpose, two anthraquinone phosphoramidites were synthesised: *N*-ethyl- and *N*-pentyl-2-anthra-
30 quinonecarboxamide phosphoramidite. The two phosphoramidites were synthesised from anthraquinone-2-carbonyl chloride, which was reacted with 2-amino-1-ethanol or 5-amino-pentanol to afford *N*-(2-hydroxyethyl)- and *N*-(5-hydroxypentyl)-2-anthraquinone-carboxamide, respectively. Reaction of these carboxamides with *N,N*-diisopropylmethylphosphonamides chloride afforded the corresponding phosphoramidites as thick dark red
35 oils after column chromatography. Coupling of these anthraquinone phosphoramidites to


the 5'-OH terminus of ODNs as the final step in a solid phase synthesis gave anthraquinone-ODN conjugates.

Large scale synthesis of anthraquinone-oligomer conjugates using automated solid phase chemistry requires readily available and relatively stable anthraquinone synthons. Initial attempts to synthesize stable anthraquinone phosphoramidite reagents revealed that the above-mentioned types of reagents appear to be unstable.

The synthesis of an anthraquinone phosphoramidite derivative of *N*-(6-hydroxyhexyl)-2-anthraquinone carboxamide using *N,N,N',N'*-tetraisopropylphosphorodiamidite and tetrazole is described in Example 1. Attempted isolation of this cyanoethyl phosphoramidite led to decomposition. Use of the crude product, after filtration of the reaction mixture, directly onto the DNA synthesizer within one day also led to decomposition. Following, attempts to prepare a cyanoethyl phosphoramidite analog of the *N*-(2-hydroxyethyl) anthraquinonecarboxamide by reaction of *N*-(2-hydroxyethyl)anthraquinonecarboxamide with 2-cyanoethyl *N,N*-diisopropylphosphoramido-chloridite in the presence of ethyldiisopropyl amine (see Example 2) or by the same procedure as described in Example 1 afforded, initially, a bright yellow foam after flash chromatography. Drying of this material under high vacuum over night resulted in a dark brown syrup, indicating decomposition. The fact that all of the above anthraquinone phosphoramidite reagents have to be used immediately after preparation makes them less suitable for synthesis of a large-scale synthesis of anthraquinone-oligomer conjugates.

SUMMARY OF THE INVENTION


The present invention relates to a stable phosphoramidite reagent, designed for automated solid phase synthesis of oligomers, of the general formula I



wherein Y and Y' each independently are selected from optionally substituted C₁₋₆-alkyl or Y and Y' together with the nitrogen to which they are bonded form a non-aromatic *N*-


heterocyclic ring; W is selected from O and S; X is selected from optionally substituted C₁₋₆-alkyl and optionally substituted benzyl; R^N is selected from hydrogen C₁₋₄-alkyl, optionally substituted benzyl, optionally substituted quinones, and nucleosides; and Q is selected from optionally substituted quinones, and optionally substituted photoreactive ketones, such as optionally substituted benzophenone.

The invention also relates to an oligomer comprising the following fragment:




wherein Q and R^N are as defined above for formula (I); W and W' are independently selected from O and S; and V is selected from optionally substituted C₁₋₆-alkyl, optionally substituted benzyl, hydrogen, Li⁺, K⁺, Na⁺, and NH₄⁺.

The present invention furthermore relates to a stable phosphoramidite reagent of the general formula II



wherein Y and Y' each independently are selected from optionally substituted C₁₋₆-alkyl or Y and Y' together with the nitrogen to which they are bonded form a non-aromatic N-heterocyclic ring; X is selected from optionally substituted C₁₋₆-alkyl and optionally substituted benzyl; W is selected from O and S; Q is selected from optionally substituted quinones and optionally substituted photoreactive ketones; n is an integer from 1 to 10; and m is 0 or 1.

The invention also relates to an oligomer comprising the following fragment:



wherein Q, n and m are as defined above for formula (II); W and W' are independently
 5 selected from O and S; and V is selected from optionally substituted C₁₋₆-alkyl, optionally substituted benzyl, hydrogen, Li⁺, K⁺, Na⁺, and NH₄⁺.

DETAILED DESCRIPTION OF THE INVENTION

10

The applicant has successfully approached covalent coupling of synthetic oligomers onto carbon-containing polymers in two different ways. In the first approach, a photoprobe, consisting of an anthraquinone or benzophenone molecule linked to an electrophilic reactive group via an ethylene glycol linker, was coupled to a polymer surface by short
 15 time exposure to UV light. Subsequently, reaction between the electrophilic groups attached to the polymer and nucleophilic aminoalkyl ONs lead to immobilization of the oligomers.


The second approach involved automated solid phase synthesis of anthraquinone-
 20 oligomers or benzophenone-oligomers. Irradiation of an aqueous solution containing either the anthraquinone-oligomers or benzophenone-oligomers with soft UV light resulted in attachment of the anthraquinone-oligomers and benzophenone-oligomers to the polymer surface through a covalent bond between the anthraquinone moiety or benzophenone moiety and the surface to which the solution has been applied.

25

The present invention describes the synthesis of surprisingly stable quinone- and photoreactive ketone phosphoramidite reagents which do not suffer from the drawbacks described above. These new reagents are easily synthesised from commercially available starting materials. Contrary to previously described 5'-end anthraquinone labelling
 30 phosphoramidites, the phosphoramidite reagents according to the present invention are isolated as stable solid materials, which can be stored for several months at -20 °C

without loss of reactivity and incorporated in an oligomer, using standard automated solid phase synthesis. Similarly, benzophenone phosphoramidites according to the present invention are isolated as stable oils, which can be stored for several months at -20 °C without loss of reactivity and incorporated in an oligomer, using standard automated solid phase synthesis.

As mentioned above, the present invention *i.a.* relates to a stable phosphoramidite reagent of the general formula I



wherein Y and Y' each independently may designate an optionally substituted C₁₋₆-alkyl or Y and Y' together with the nitrogen to which they are bonded form a non-aromatic N-heterocyclic ring.

Among the possible Y and Y', the situation where Y and Y' each designate ethyl or isopropyl, or together designate pyrrolidino, piperidino or morpholino seem especially interesting, and the situation where Y and Y' both are isopropyl appears to be particularly interesting.

The substituent X is selected from the group consisting of optionally substituted C₁₋₆-alkyl and benzyl. Examples of optionally substituted C₁₋₆-alkyl are methyl, 2-cyanoethyl, 2-(4-nitrophenyl)ethyl, 2-(2-pyridyl)ethyl, 2-(4-pyridyl)ethyl, and 2-(C₁₋₆-alkylsulfonyl)ethyl among which 2-cyanoethyl presently is the most preferred.

W is selected from O and S where O is most preferred.

R^N is selected from hydrogen and C₁₋₄-alkyl, such as methyl, ethyl, and isopropyl, optionally substituted benzyl, optionally substituted quinones attached via suitable linkers, e.g. methylene and polymethylene, and nucleosides attached via 5'-C through a methylene or polymethylene linker; preferably R^N designates hydrogen.

Q represents a group selected from optionally substituted quinones and optionally substituted photoreactive ketones.


By the term "quinone" is understood a dihydroaromatic system wherein the -CH₂- groups
5 are replaced by -C(=O)-. In the present context "quinone" covers quinones derived from di- or tetrahydroaromatic systems comprised by 1 to 5 fused carbon cyclic rings.

Illustrative examples of such quinones are derived from 1,4-benzoquinone, 1,2-benzoquinone, naphthoquinone, anthraquinone, phenanthrenequinone, alizarin, rubiadin, lucidin, damnacanthal, munjistin, chrysophanol, frangula-emodin, aloe-emodin,
10 morindone, and copareolatin. As mentioned above, quinones may be optionally substituted, however, it is presently believed that unsubstituted quinones, in particular unsubstituted anthraquinone and phenanthrenequinone, are especially preferred.


Examples of particular interesting photoreactive ketones are acetophenone,
15 benzophenone, anthrone and anthrone-like heterocycles, *i.e.* anthrone wherein the group in 10-position is replaced by O, S, or NH. The photoreactive ketones can be optionally substituted as described below. Particular interesting photoreactive ketones are benzophenone and acetophenone of which unsubstituted benzophenone is presently most preferred.

20


In a preferred embodiment of the present invention, the phosphoramidite has the following structure:



In a preferred embodiment of the present invention, the phosphoramidite has the following
25 structure:




When coupled to oligomers, *e.g.* ONs or ODNs, the reagents of the present invention lead to a novel class of oligomers. Thus, the invention furthermore relates to an oligomer comprising the following fragment:



5

wherein Q and R^N are as defined above for formula (I), W and W' are independently selected from O and S, V is selected from optionally substituted C₁₋₆-alkyl, optionally substituted benzyl, hydrogen, Li⁺, K⁺, Na⁺, and NH₄⁺ and "oligomer" has the meaning defined below. In a preferred embodiment, Q represents anthraquinone, R^N represent
10 hydrogen, W and W' both represent O, and V is hydrogen.

The invention also relates to a phosphoramidite reagent of the formula II



wherein Y and Y' each independently may designate an optionally substituted C₁₋₆-alkyl or
15 Y and Y' together with the nitrogen to which they are bonded form a non-aromatic N-heterocyclic ring.

Among the possible Y and Y', the situation where Y and Y' each designate ethyl or isopropyl, or together designate pyrrolidino, piperidino or morpholino seem especially
20 interesting, and the situation where Y and Y' both are isopropyl appears to be particularly interesting.

The substituent X is selected from the group consisting of optionally substituted C₁₋₆-alkyl and benzyl. Examples of optionally substituted C₁₋₆-alkyl are methyl, 2-cyanoethyl, 2-(4-nitrophenyl)ethyl, 2-(2-pyridyl)ethyl, 2-(4-pyridyl)ethyl, and 2-(C₁₋₆-alkylsulfonyl)ethyl
5 among which 2-cyanoethyl presently is the most preferred.

W is selected from O and S where O is most preferred.

Q represent a group selected from optionally substituted quinones and optionally
10 substituted photoreactive ketones. Illustrative examples of such quinones are derived from phenanthrenequinone, 1,4-benzoquinone, 1,2-benzoquinone, naphthoquinone, anthraquinone, alizarin, rubiadin, lucidin, damnacanthal, munjistin, chrysophanol, frangula-emodin, aloe-emodin, morindone, and copareolatin. As mentioned above, quinones may be optionally substituted, however, it is presently believed that
15 unsubstituted quinones, in particular unsubstituted anthraquinone and phenanthrenequinone, are especially preferred.


Examples of particular interesting optionally substituted photoreactive ketones are benzophenone, amino-, hydroxyl-, halogen-, acyl-, nitro-, and cyanobenzophenone, of
20 which unsubstituted benzophenone is presently most preferred.

n is an integer from 1 to 10. It is presently believed that variants where n is ranging from 1 to 4, such as 1, 2, 3 or 4, are particularly relevant.

25 m is 0 or 1.

In a preferred embodiment, Y and Y' both are isopropyl and X designates 2-cyanoethyl

Coupling of phosphoramidite reagents of the general formula II to the termini of an
30 oligomer affords oligomers containing the following fragment. Thus, the invention also relates to an oligomer comprising this fragment:



wherein Q, n and m are as defined above for formula (II), W and W' are independently selected from O and S, and V is selected from optionally substituted C₁₋₆-alkyl, optionally substituted benzyl, hydrogen, Li⁺, K⁺, Na⁺, and NH₄⁺ and "oligomer" has the meaning
 5 defined below. In a preferred embodiment, Q represents anthraquinone or phenanthrenequinone, W and W' both represent O, V is hydrogen, n is 1, and m is 0.

It should also be understood that the phosphoramidite reagents of the general formulas I and II can be coupled to the 3'-OH termini of an oligomer synthesized from 5'→3'.

10

Preparation of phosphoramidite reagents

In a preferred embodiment, anthraquinone phosphoramidites were synthesised by the following procedures:

15

Synthesis of the anthraquinone phosphoramidite **3** is illustrated in Figure 1 and was performed in two steps starting from commercially available anthraquinone-2-carboxylic acid (**1**). Coupling of compound **1** with 3-amino-1-propanol in the presence of benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP) yielded
 20 the amide **2**. Subsequently, phosphitylation of **2** using 2-cyanoethyl-*N,N*-diisopropylphosphoramido-chloridite afforded the anthraquinone phosphoramidite **3** as a red oil after aqueous workup. Redissolution of the crude product **3** in a minimum amount of anhydrous methylenechloride and subsequent precipitation in vigorously stirred petroleum ether at 0 °C afforded **3** as a bright yellow powder. The product **3** was dried
 25 overnight at high vacuum and stored under nitrogen at -20 °C.

Synthesis of the anthraquinone phosphoramidite **5** is illustrated in Figure 1 and was performed in one step starting from commercial available 2-(hydroxymethyl)anthraquinone (**4**). Phosphitylation of 2-(hydroxymethyl)anthraquinone (**4**) using the same procedure as
 30 described for the preparation of **3** afforded the corresponding phosphoramidite **5** as a

yellow oil, which was coevaporated with anhydrous acetonitrile to afford **5** as a yellow solid material.

Alternatively, reaction of 2-(hydroxymethyl)anthraquinone (**4**) with 2-cyanoethyl-*N,N,N',N'*-tetraisopropylphosphorodiamidite and tetrazole afforded the phosphoramidite **5** as a bright yellow solid material after filtration and aqueous workup.

Phosphoramidite **3** has been used in automated solid phase synthesis for a large number of anthraquinone-ODN conjugates. The phosphoramidite **3** was coupled directly to the 5'-OH termini of an ODN or via a 5'-hexaethyloxyglycol spacer (SpacerTM) to an ODN as the final step in an automated solid phase synthesis on a Gene Assembler Special[®] synthesiser using a 0.1 M solution and a 5 min. coupling time. The coupling efficiency was estimated to be >98% as attempted coupling of another thymidine nucleoside (T) residue to a test sequence 5'-anthraquinone-T-3' failed completely (no 4,4'-dimethoxytrityl-release was monitored). The two general types of anthraquinone oligonucleotide synthesised are illustrated in Figure 2.

In a preferred embodiment, optionally substituted photoreactive ketone phosphoramidites, such as benzophenone phosphoramidites, were synthesised by the following procedures:

Synthesis of the anthraquinone phosphoramidite **8** was performed in two steps starting from commercially available benzoylbenzoic acid (**6**). Coupling of compound **6** with 3-amino-1-propanol in the presence of benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP) yielded the amide **7**. Subsequently, phosphitylation of **7** using 2-cyanoethyl-*N,N*-diisopropylphosphoramido-chloridite afforded the benzophenone phosphoramidite **8** as a pale yellow oil. This oil was used without further purification and stored under nitrogen at -20 °C.

Figure 3 illustrates the synthesis of a benzophenone-phosphoramidite reagent. Its application for the preparation of benzophenone-oligonucleotide conjugates was analogous to that outlined in Figure 2 for anthraquinone oligonucleotide conjugates.

Phosphoramidite **8** has been used in automated solid phase synthesis for a large number of anthraquinone-ODN conjugates. The phosphoramidite **8** may be coupled directly to the 5'-OH termini of an ODN or via a 5'-hexaethyloxyglycol spacer (SpacerTM) to an ODN as

the final step in an automated solid phase synthesis on a Gene Assembler Special® synthesiser using a 0.2 M solution and a 15 min. coupling time.

DNA oligomers carrying a 5'anthraquinone or a 5'benzophenone can be covalently
5 immobilised on a solid support by irradiation and the immobilised oligomers are efficient in the capture of a complementary DNA oligomer.

As shown in Figures 6 and 7, both the AQ oligomers and the BP oligomers yield a clearly concentration dependent signal. When using a non-complementary sequence, no signal
10 could be detected. It is concluded that both anthraquinone and optionally substituted photoreactive ketone oligomers, such as AQ and BP oligomers, can be covalently attached to a solid surface by irradiation and that oligomers attached in this way are able to hybridise to their complementary target DNA oligomers.

15 DEFINITIONS

In the present context, the term "C₁₋₆-alkyl" means a linear, cyclic or branched hydrocarbon group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, *iso*-propyl, pentyl, cyclopentyl, hexyl, cyclohexyl, preferred examples of "C₁₋₆-alkyl" are ethyl, propyl,
20 *iso*-propyl, butyl, *tert*-butyl, *iso*-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, in particular ethyl. Analogously, the term "C₁₋₄-alkyl" means a linear, cyclic or branched hydrocarbon group having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, *iso*-propyl, butyl, *iso*-butyl, and *tert*-butyl.

25 In the present context, *i.e.* in connection with the terms "alkyl", "quinone" and "photoreactive ketones", the term "optionally substituted" means that the group in question may be substituted one or several times, preferably 1-4 times, with group(s) selected from hydroxyl, amino, halogen, acyl, nitro and cyano, C₁₋₆-alkoxy, C₁₋₆-alkyl (only relevant for quinone and photoreactive ketones), formyl, carboxyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkylcarbonyl, aryl, aryloxycarbonyl, arylcarbonyl, heteroaryl, mono- and di(C₁₋₆-alkyl)amino, carbamoyl, mono- and di(C₁₋₆-alkyl)aminocarbonyl, amino-C₁₋₆-alkyl-amino-carbonyl, mono- and di(C₁₋₆-alkyl)amino-C₁₋₆-alkyl-aminocarbonyl, C₁₋₆-alkylcarbonylamino, carbamido, where C₁₋₆-alkyl, aryl and heteroaryl may be substituted 1-5 times,
30 preferably 1-3 times, with hydroxyl, acyl, C₁₋₄-alkyl, C₁₋₄-alkoxy, nitro, cyano, amino or halogen.

"Halogen" includes fluoro, chloro, bromo, and iodo.

In the present context, the term "oligomer(s)" means oligonucleotides (ONs),
5 oligodeoxynucleotides (ODNs), and derivatives thereof, such as ONs/ODNs modified in
the carbohydrate moiety, *e.g.* Locked Nucleoside Analogues (LNAs), ONs/ODNs modified
in the phosphodiester linkage, *e.g.* phosphorothioates, phosphoramidates, and
methylphosphonates, ONs/ODNs modified in the heterocyclic base, and "backbone"
modified ONs/ODNs, *e.g.* Peptide Nucleic Acids (PNAs). The oligomers may be from
10 1-1000 units, *e.g.* 1-1000 nucleotides, preferably 1-200, even more preferably 5-30 units,
and each oligomer may comprise different classes of units, *e.g.* ODN-LNA conjugate.
It should also be understood that the term "oligomer" means oligomers synthesized from
3'→5', terminating in a 5'-OH, as well as oligomers synthesized from 5'→3', terminating in
a 3'-OH.

15

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 illustrates the synthesis of anthraquinone phosphoramidites **3** and **5**.

20 Figure 2 illustrates the synthesis of two general types of anthraquinone oligonucleotide
synthesised.

Figure 3 illustrates the synthesis of a benzophenone-phosphoramidite reagent. Its
application for the preparation of benzophenone-oligonucleotide conjugates was
25 analogous to that outlined in Figure 2 for anthraquinone oligonucleotide conjugates.

Figure 4 illustrates that the anthraquinone-ODN conjugates 1-6 (Table 1) capture their
specific complimentary biotinylated oligomers very efficiently and significantly better than
the corresponding unmodified control-ODN capture probes A and B. No signal is
30 observed when the capture probes are incubated with the unrelated complimentary
biotinylated ODNs.

Figure 5

The 6 scans represent one array each. Each array is an individual analysis and is
35 performed on individual slides. Before hybridisation with a sample, an array of AQ-

oligonucleotides has been arranged on the slides and immobilised via UV-irradiation. The template after which the spots on the array are arranged is illustrated below:

Neg	ON8	ON8	ON7
ON9	ON7	Neg	ON9
ON9	Neg	ON7	ON8
ON7	ON8	ON9	Neg

wherein Neg represents a negative control, ON8 is a mutant catching probe, ON7 is a positive control, and ON9 is a wildtype catching probe. This pattern is repeated 4 times (2×2) on each slide.

The 6 samples analysed here are:

1. A homogeneous wildtype including a positive control.
 Only the "wildtype spots" and the "positive control spots" light up on this slide, and thus it is possible to determine the "genotype" of the analysed sample to be homogeneous wildtype.
2. A homogeneous mutant including a positive control.
 Only the "mutant spots" and the "positive control spots" light up on this slide, and thus it is possible to determine the "genotype" of the analysed sample to be homogeneous mutant.
3. A heterozygote including a positive control.
 Both the "wildtype spots", the "mutant spots" and the "positive control spots" light up on this slide, and thus it is possible to determine the "genotype" of the analysed sample to be heterogeneous wildtype.
4. A heterozygote without positive control.
 As in 3), both the "wildtype spots", the "mutant spots", and thus it is possible to determine the "genotype" of the analysed sample to be heterogeneous wildtype. The "positive control spots" does not light up as no positive control oligo was added to the sample during preparation, thus it is possible to rule out "cross talk"/unspecific hybridisation of the samples to the positive control spots.
5. Positive control alone.
 Since no sample is present during hybridisation only the positive control spots light up, thus it is possible to rule out "cross talk" between the positive control and the "wildtype" and "mutant spots".

6. Blank (negative control).

When an array is hybridised with a buffer containing no sample or controls, no signal is obtained from any of the spots.

- 5 The signal strength from the mutant and the wildtype spots in slide 1, 2 and 3 were quantified with a dedicated program (Optiquant), and the results presented as a bar diagram in Figure 5B.

Figure 6 illustrates the immobilisation efficiency as a function of anthraquinone and
10 benzophenone coupled oligonucleotide in 0.2 M NaCl of type A sequence.

Figure 7 illustrates the immobilisation efficiency as a function of anthraquinone and benzophenone coupled oligonucleotide in 0.2 M NaCl of type B sequence.

EXPERIMENTAL

Example 1

N-(6-hydroxyhexyl)-2-anthraquinone carboxamide (193 mg, 0.55 mmol) was dried by
5 evaporation once with dry acetonitrile and suspended in dry acetonitrile (5 ml) under
nitrogen. To this suspension was added 2-cyanoethyl *N,N,N',N'*-tetraisopropyl-
phosphorodiamidite (150 mg, 0.50 mmol) and tetrazole (1.0 ml of a 0.43 M solution in
acetonitrile, 0.43 mmol). The mixture was stirred and heated to 40°C for 1 h, stirred
overnight at room temperature, and heated to 40°C for a further period (usually 3–4 h),
10 until ³¹P-NMR showed that all the phosphorus reagent had reacted (signals at 123 and
132 ppm absent, the product is at 146.4 ppm). The reaction mixture (a thick slurry) was
filtered under nitrogen (Bio-Rad Poly-Prep Column used as filter) and the residue washed
with dry acetonitrile to bring the filtrate to ca. 5 ml. This solution (ca. 0.1 M in
phosphoramidite) was used directly on the DNA synthesizer within a day. The
15 phosphoramidite slowly decomposes in solution at room temperature, and attempts to
isolate it resulted in decomposition.

Example 2

To a suspension of *N*-(2-hydroxyethyl)-2-anthraquinone carboxamide (500 mg, 1.69
20 mmol) in dry CH₂Cl₂ (5 ml) under N₂, was added diisopropylethyl amine (1.0 ml, 5.74
mmol) followed by dropwise addition of 2-cyanoethyl *N,N*-diisopropylphosphoramido-
chloridite (0.38 ml, 1.70 mmol). The resulting clear yellow solution was stirred at room
temperature for 30 min, then poured into ethyl acetate (10 ml) containing triethylamine (1
ml). The mixture was washed with saturated aqueous NaHCO₃ (2 x 5 ml) and brine (2 x 5
25 ml), dried (Na₂SO₄) and evaporated under reduced pressure. The residue was subjected
to column chromatography on silica gel (eluent: 45:45:10, ethyl acetate:petroleum
ether:triethyl amine) and gave 640 mg of a yellow syrup, which turned into a dark red gum
after drying overnight under high vacuum.

30 Treatment of *N*-(2-hydroxyethyl)-2-anthraquinone carboxamide (510 mg, 1.73 mmol) with
2-cyanoethyl *N,N,N',N'*-tetraisopropylphosphorodiamidite (0.55 ml, 1.73 mmol) and
tetrazole (3.65 ml of a 0.45 M solution in acetonitrile, 1.64 mmol) in dry CH₂Cl₂ (20 ml) for
120 min. at room temperature, gave after filtration of the reaction mixture and aqueous
workup and evaporation of the solvents a yellow foam, which collapsed into a dark-brown
35 syrup after drying overnight under high vacuum.

Example 3**Preparation of *N*-(3-hydroxypropyl)-2-anthraquinonecarboxamide (2).**

To a stirred suspension of anthraquinone-2-carboxylic acid (Aldrich, 10.00 g, 39.64 mmol) in DMF (130 ml), was added (benzotriazol-1-yloxy)tris(dimethylamino)-phosphonium hexafluorophosphate (17.54 g, 39.66 mmol) and triethylamine (11.05 ml, 79.28 mmol). The resulting mixture (initially a clear green solution) was stirred at room temperature for 10 min. before dropwise addition of 3-amino-1-propanol (3.34 ml, 43.67 mmol). The reaction mixture (clear brown solution) was stirred at room temperature in the dark for 17 hours. The solution was poured in a thin stream into water (300 ml) containing some ice. The precipitated material was isolated by filtration and recrystallised from boiling 96% ethanol (ca. 200 ml) and gave the title compound **2** as a bright yew solid (6.93 g, 57% yield).

¹H NMR (250 MHz, DMSO-*d*₆) δ: 1.74 (2H, quintet, *J* = 6.52 Hz, CH₂), 3.25-3.44 (2H, m, CH₂), 3.50 (2H, broad t, *J* = 5.80 Hz, CH₂), 4.53 (1H, broad s, OH), 7.76-8.00 (2H, m, Ar), 8.04-8.36 (4H, m, Ar), 8.56 (1H, d, *J* = 1.55 Hz, Ar), 8.89 (1H, t, *J* = 5.42 Hz, NH). ¹³C NMR (250 MHz, DMSO-*d*₆) δ: 32.32, 36.96, 58.68, 125.50, 126.83, 126.85, 127.05, 132.79, 133.04, 133.08, 134.45, 134.66, 139.49, 164.62, 182.11.

Example 4**Preparation of *N*-(3-(2-cyanoethoxy(diisopropylamino)phosphinoxy)propyl)-2-anthraquinonecarboxamide (3).**

N-(3-Hydroxypropyl)-2-anthraquinonecarboxamide (**2**) (1.00 g, 3.23 mmol) was suspended in anhydrous CH₂Cl₂ (30 ml) under N₂. *N,N*-diisopropylethylamine (1.24 ml, 7.12 mmol) was added with stirring followed by dropwise addition of 2-cyanoethyl *N,N*-diisopropylphosphoramidochloridite (0.72 ml, 3.23 mmol). The resulting slightly turbid reaction mixture was stirred at room temperature for 25 min. The mixture was filtrated and diluted with ethyl acetate (100 ml) containing triethylamine (10 ml) and washed with saturated aqueous NaHCO₃ (2 x 20 ml). The organic solution was dried (Na₂SO₄) and evaporated under reduced pressure. The residue was dissolved in a minimum amount of CH₂Cl₂ and added dropwise to vigorously stirred ice cooled light petroleum ether (200 ml). The precipitated yellow powder was collected by filtration and dried overnight under high vacuum affording **3** (1.26 g, 77% yield). This compound could be stored under N₂ at – 20°C for several months without significant decomposition: ¹H NMR (250 MHz, CDCl₃) δ: 1.17 (d, *J* = 6.86 Hz, CH₃), 1.87-2.15 (m, CH₂), 2.70 (t, *J* = 5.72 Hz, CH₂), 3.41-4.04 (m,

CH₂, CH), 7.17 (broad t, *J* = 5.49 Hz, NH), 7.76-7.87 (m, Ar), 8.24-8.41 (m, Ar), 8.59 (d, *J* = 1.65 Hz, Ar). ¹³C NMR (250 MHz, CDCl₃) δ: 20.43, 20.54, 24.58, 24.69, 30.22, 30.33, 38.53, 43.03, 43.23, 58.19, 58.51, 62.45, 62.74, 117.90, 125.04, 127.39, 127.83, 133.15, 133.42, 134.39, 135.04, 139.80, 165.57, 182.50. ³¹P NMR (CDCl₃) δ: 148.49.

5

Example 5

Preparation of 2-[2-cyanoethoxy(diisopropylamino)phosphinoxymethyl]-anthraquinone (5).

To a stirred suspension of 2-(hydroxymethyl)anthraquinone (Fluka, 1.00 g, 4.20 mmol) in anhydrous CH₂Cl₂ (42 ml) under N₂, was added 2-cyanoethyl *N,N,N',N'*-tetraisopropylphosphorodiamidite (1.33 ml, 4.20 mmol) followed by dropwise addition of tetrazole (8.86 ml of a 0.45 M sol. in CH₃CN). The reaction mixture was stirred at room temperature for 90 min. and the resultant salts were filtrated off. The filtrate was diluted with CH₂Cl₂ (50 ml) and washed with saturated aqueous NaHCO₃ (2 x 20 ml) and brine (20 ml). The organic solution was dried (Na₂SO₄) and evaporated under reduced pressure. The remaining yellow solid material was co-evaporated with anhydrous CH₃CN and dried over night under high vacuum yielding **5** as bright yellow solid (1.84 g, 100 % yield).

¹H NMR (400 MHz, CDCl₃) δ: 1.23 (d, *J* = 6.96 Hz, CH₃), 2.69 (t, *J* = 6.41 Hz, CH₂), 3.65-3.75 (m, CH), 3.84-3.97 (m, CH₂), 4.82-4.95 (m, CH₂), 7.77-7.82 (m, Ar), 8.27-8.32 (m, Ar). ¹³C NMR (400 MHz, CDCl₃) δ: 20.29, 20.35, 24.50, 24.57, 43.13, 43.26, 58.32, 58.51, 64.48, 64.66, 117.40, 125.03, 127.04, 127.10, 127.41, 132.01, 132.21, 132.48, 133.37, 133.39, 133.89, 133.96, 134.07, 145.95, 146.03, 182.68, 182.89. ³¹P NMR (CDCl₃) δ: 149.76.

25

Example 6

Preparation of 5'-end anthraquinone-ONs

Initially, an unmodified ODN sequence was synthesised on a DNA-synthesizer (Pharmacia Gene Assembler Special[®]) using standard phosphoramidites coupling conditions according to the protocol (0.2 μmol or 1.3 μmol scale) and standard 2'-deoxynucleoside CPG or polystyrene solid supports. While still on the synthesizer, the 5'-OH termini of the ODN sequence was coupled with the phosphoramidite reagent (**3**) or (**5**) using a 0.1 M solution and a 5 min. coupling time. The coupling efficiency was estimated to be >98% as attempted coupling of another thymidine nucleoside (T) residue to a test

sequence 5'-anthraquinone-T-3' failed completely (no 4,4'-dimethoxytrityl-release was monitored).

After completion of the synthesis, the desired anthraquinone-ODN was cleaved from the solid support and the nucleobase protection groups were removed by incubation with 32% NH₄OH at 55-60°C for 10-15 hours. The crude anthraquinone-ODN-conjugate was purified by reversed-phase HPLC (C-18, 100 Å, 15 m, 300 x 3.9 mm ID) in a gradient from 100 % 0.05M triethylammonium acetate (pH 7.4) to 100 % H₂O(50%)/CH₃CN(50%), v/v.

10 Table 1: Examples of synthesized anthraquinone-ODN conjugates:

1	5'-AQCONH(CH ₂) ₃ -aacagctatgaccatg-3'
2	5'-AQCONH(CH ₂) ₃ -HEG-aacagctatgaccatg-3'
3	5'-AQCONH(CH ₂) ₃ -(HEG) ₂ -aacagctatgaccatg-3'
4	5'-AQCONH(CH ₂) ₃ -gtaaaacgacggccagt-3'
5	5'-AQCONH(CH ₂) ₃ -HEG-gtaaaacgacggccagt-3'
6	5'-AQCONH(CH ₂) ₃ -(HEG) ₂ -gtaaaacgacggccagt-3'
7	5'-AQCONH(CH ₂) ₃ -HEG-attaatgctatgcagaaaatctta g-3'
8	5'-AQCONH(CH ₂) ₃ -“15-mer non-binding DNA sequence”-GACCGTGTg-3'
9	5'-AQCONH(CH ₂) ₃ -“15-mer non-binding DNA sequence”-GACTGTGTg-3'
10	5'-AQCH ₂ -(CH ₂) ₃ -gtaaaacgacggccagt-3'
11	5'-AQCH ₂ -(CH ₂) ₃ -aacagctatgaccatg-3'

AQCONH = anthraquinone-2-carboxamide. HEG = hexaethyloxyglycol. ON-sequence: lowercase = normal 2'-deoxynucleoside monomers; uppercase = modified nucleosides (Locked Nucleic Acids) LNA™.

15 Example 7

Photoimmobilised anthraquinone-ODN conjugates efficiently and specifically hybridises with complementary ODNs in Microtiter plates.

Anthraquinone-ODN conjugates 1-6 (Table 1) and unmodified controls ODN-A (5'-aacagctatgaccatg-3') and ODN-B (5'-gtaaaacgacggccagt-3') were synthesised as described. All of the ODNs were diluted in 0.2 M LiCl to a final concentration of 0.1 µM and 100 µL per well were dispensed into a microtiter-plate (MTP, Nunc, Polysorp). The ODN solutions were irradiated for 15 minutes under soft UV light. After irradiation the MTP was washed four times with 300 µL demineralised water.

100 μL per well of 0.004 μM complimentary biotinylated oligomers either 5'-biotin-catggcatagctgtt-3' (biotin-comp. ODN-A) or 5'-biotin-actggccgctcgttttac-3' (biotin-comp ODN-B) were hybridised to the immobilised oligomers in 2 x SSCT (30 mM citrate, 0.3 M NaCl, pH 7.0, 0.1% (v/v) Tween 20) at room temperature for two hours. After washing
5 three times with 300 μL 1 x SSCT (15 mM citrate, 0.15 M NaCl, pH 7.0, 0.1% (v/v) Tween 20) and one time phosphate buffered saline (PBST, 0.15 M Na^+ , pH 7.2, 0.05% (v/v) Tween 20) 100 μL per well 1 $\mu\text{g/mL}$ horse radish peroxidase conjugated streptavidin (Pierce) was added to the MTP. The MTP was incubated for 30 minutes at room temperature and washed three times with 300 μL PBST.

10

Wells were assayed for peroxidase activity by adding 100 μL of substrate solution (0.1 mL citrate-phosphate buffer pH 5.0, 0.66 mg/mL ortho-phenylenediamine dihydrochloride, 0.012% (v/v) H_2O_2) the reaction was stopped after 30 minutes by adding 100 μL 0.5 M H_2SO_4 and the absorbance at 492 nm was read in a microtiter-plate reader.

15

As shown in Figure 4, the anthraquinone-ODN conjugates 1-6 (Table 1) capture their specific complimentary biotinylated oligomers very efficiently and significantly better than the corresponding unmodified control-ODN capture probes A and B. No signal is observed when the capture probes are incubated with the unrelated complimentary

20 biotinylated ODNs.

Example 8

Detection of a single nucleotide polymorphism (SNP) with an array of anthraquinone-ON conjugates.

25 Four solutions of ArrayIt™ Spotting Solution (Telechem, Lot. 99301) were prepared.

Solution 1 (positive control): 7 μM ON7 (Table 1), solution 2 (negative control): Pure spotting solution (Neg), solution 3 (wildtype catching probe): 7 μM ON8 (Table 1) and solution 4 (mutant catching probe): 7 μM ON9 (Table 1).

30 A Cartesian Tech PixSys 3500 spotting robot was programmed to array the 4 different solutions from a microtitre plate onto silanised slides (Manufacturer, Lot.No.). The spots were positioned 1 mm apart in a 4 by 4 array at 30 nL each, 4 replica of each solution according to the following template:

35

Neg	ON8	ON8	ON7
ON9	ON7	Neg	ON9
ON9	Neg	ON7	ON8
ON7	ON8	ON9	Neg

Subsequent to spotting the spots were allowed to dry for 10 min. at room temperature and then irradiated with UV light for 30 min in a ULS–20–2 illuminator using both upper and lower light and a glass plate holder. Finally the slides were washed in 3×10 min. with Milli-
 5 Q water (ca. 100 mL pr. 25 slides).

In a hybridisation assay, six spotted slides were incubated with different combinations of sample, reporter system and positive controls as described below. Two synthetic 50-mer ODN's, one displaying the mutant- (MT) and one displaying the wildtype (WT) nucleotide
 10 sequence of the gene containing the SNP in question, were used as samples. To detect if any sample 50-mer had hybridised to the immobilised catching probes, a 25-mer ODN detection probe complementary to a sequence common to both mutant and wildtype 50-
 15 mers, and marked with a biotin in the 5'-end, was used (5'–Biotin–ttggaagtgccctgcagctt–3', ODN-Bio). The presence of biotin was detected by incubation with Cy5-labeled streptavidin (SA/Cy5). As positive control was used a ODN complementary to ON7 and
 marked with a Cy5 fluorophore in the 5'-end (Pos–Cy5: 3'–ctaagatttctgcatagcattaat–Cy5–5').

The slides were incubated with 20 µL of hybridisation mix under a cover slide at 37°C for
 20 30 min. The following six different hybridisation mixtures were used (all in 2×SSC):

1. "Homozygote" wildtype sample @ 0.1 µM:
 - 3.6 µL WT 50-mer (Stock: 2.8 µM)
 - 47.2 µL ODN-Bio (Stock: 1.06 µM)
 - 1.0 µL Pos–Cy5 (Stock: 1.0 µM)
 - 40 µL 5×SSC, 0.1% SDS (2×SSC final)
 - 8.2 µL Milli-Q water.
2. "Homozygote" mutant sample @ 0.1 µM:
 - 7.1 µL MT 50-mer (Stock: 1.4 µM)
 - 47.2 µL ODN-Bio (Stock: 1.06 µM)
 - 1.0 µL Pos–Cy5 (Stock: 1.0 µM)

- 40 μL 5 \times SSC, 0.1% SDS (2 \times SSC final)
4.7 μL Milli-Q water.
- 5 3. "Heterozygote" sample @ 0.1 μM :
3.6 μL WT 50-mer (Stock: 2.8 μM)
7.1 μL MT 50-mer (Stock: 1.4 μM)
47.2 μL ODN-Bio (Stock: 1.06 μM)
1.0 μL Pos-Cy5 (Stock: 1.0 μM)
40 μL 5 \times SSC, 0.1% SDS (2 \times SSC final)
1.1 μL Milli-Q water.
- 10 4. "Heterozygote" sample @ 0.1 μM , + Pos-Cy5:
3.6 μL WT 50-mer (Stock: 2.8 μM)
7.1 μL MT 50-mer (Stock: 1.4 μM)
47.2 μL ODN-Bio (Stock: 1.06 μM)
40 μL 5 \times SSC, 0.1% SDS (2 \times SSC final)
2.1 μL Milli-Q water.
- 15 5. Positive control only @ 0.01 μM :
1.0 μL Pos-Cy5 (Stock: 1.0 μM)
40 μL 5 \times SSC, 0.1% SDS (2 \times SSC final)
59 μL Milli-Q water.
- 20 6. Detection oligo only @ 0.5 μM :
47.2 μL ODN-Bio (Stock: 1.06 μM)
40 μL 5 \times SSC, 0.1% SDS (2 \times SSC final)
12.8 μL Milli-Q water.
- 25 Following hybridisation, the slides were washed 3 \times 5 min with 1 \times SSC/0.1% SDS (ca. 50
mL pr. 6 slides) at room temperature, and hybridised with 20 μL SA/Cy5 (2.5 $\mu\text{g}/\text{mL}$ in
2 \times SSC) under a cover slide at room temperature for 30 min. Finally the slides were
washed 3 \times 5 min in 1 \times SSC/0.1% SDS (ca. 50 mL pr. 6 slides), air dried and read in a
confocal laser scanner (Figure 5A). The tiff-image from the laser scanner was analysed
30 using a dedicated image analysis software and the resulting bar-diagram is viewed in
Figure 5B. It clearly demonstrates that the AQ oligos can be used for efficient production
of high quality oligonucleotide arrays.

Example 9**Preparation of *N*-(3-hydroxypropyl)-2-benzophenonecarboxamide (7).**

To a solution of 4-benzoylbenzoic acid (Fluka, >98%, 5.0g, 22.1 mmol) in HPLC grade DMF (70 ml), was added BOP (10.26 g, 23.20 mmol) and triethylamine (5.88 ml, 42.19 mmol) and the resulting mixture was stirred at room temperature for 10 min. 3-Amino-1-propanol (1.78 ml, 23.27 mmol) was added and the reaction mixture was stirred overnight at room temperature. The dark yellow solution was poured into water (400 ml) and the product was extracted with ethyl acetate (3 x 250 ml). The combined organic layers were washed with brine (100 ml), dried (Na₂SO₄) and evaporated under reduced pressure. The residual yellow syrup, which solidified on standing, was recrystallised from ethyl acetate and hexane yielding compound **7** as an off-white solid material (2.38 g, 38% yield).

¹H NMR (400 MHz, CDCl₃) δ: 1.83 (2H, quintet, *J* = 5.86 Hz, CH₂), 3.65 (2H, "q", *J* = 5.85 Hz, CH₂), 3.76 (2H, t, *J* = 5.68 Hz, CH₂), 7.46-7.89 (9H, m, Ar). ¹³C NMR (400 MHz, CDCl₃) δ: 31.60, 37.66, 60.14, 126.81, 128.30, 129.88, 132.79, 136.75, 137.41, 139.86, 167.29, 195.93.

Preparation of *N*-(3-(2-cyanoethoxy(diisopropylamino)phosphinoxy)propyl)-2-benzophenonecarboxamide (8).

Alcohol **7** (500 mg, 1.76 mmol) was dissolved in dry CH₂Cl₂ (15 ml) under N₂. 2-Cyanoethyl *N,N,N',N'*-teraisopropylphosphorodiamidite (0.56 ml, 1.76 mmol) and tetrazole (3.80 ml of a 0.45 M sol. in CH₃CN, 1.71 mmol) was added and the reaction mixture was stirred at room temperature for 120 min. The formed solid material (tetrazolium salts) was removed by filtration and washed with CH₂Cl₂ (20 ml). The combined clear filtrates were washed with saturated aqueous NaHCO₃ (2 x 30 ml), dried (Na₂SO₄) and evaporated under reduced pressure. The crude product was dried under high vacuum affording the phosphoramidite **8** as a pale yellow oil (812 mg, 95% yield), which was used without further purification. ³¹P NMR (CDCl₃) δ: 148.45.

Attempted precipitation of phosphoramidite **8** (obtained by phosphorylation of **7** with 2-cyanoethyl *N,N*-phosphoramidochloridite in the presence of *N,N*-diisopropylethylamine) from CH₂Cl₂ or toluene in hexane was not possible, indicating that this material is an oil by nature. However the phosphoramidite **8** can be stored at -20°C under N₂ for several weeks and possibly months without decomposition.

Example 10**Preparation of 5'-end benzophenone(BP)-oligodeoxynucleotide(ODN) conjugates.**

The following two BP-ODN conjugates were synthesized on an EXPEDITE™ 8909 DNA-synthesizer:

- 5 1) 5'-BP-CONH(CH₂)₃-HEG-gtaaacgacggccagt-3'
- 2) 5'-BP-CONH(CH₂)₃-HEG-aacagctatgaccatg-3'

Standard phosphoramidite coupling conditions according to the protocol of the synthesizer (0.2 μmol scale) and standard 2'-deoxynucleoside CPG solid supports were used to
10 prepare the above oligonucleotide sequences. While still on the synthesizer the 5'-OH termini of the ODNs were coupled with the benzophenone phosphoramidite reagent **8**, using a 0.1 M sol. in CH₃CN and standard coupling time (100 sec.). The coupling efficiency of **8** was estimated to be >98% as attempted coupling of another thymidine nucleoside residue to a test sequence: 5'-BP-t-3' failed (with capping disconnected, no
15 4,4'-dimethoxytrityl-release was observed).

The above BP-ODNs were cleaved from the solid support, deblocked and purified as described previously (Example 6).

- 20 The composition of the benzophenone containing oligodeoxynucleotides was verified by MALDI-TOF

DNA oligomers carrying a 5'-anthraquinone or a 5'-benzophenone can be covalently immobilized on a solid support by irradiation and the immobilized oligomers are efficient in
25 the capture of a complementary DNA oligomer.

Anthraquinone (AQ) and benzoephenone (BP) oligonucleotides were diluted in water and the concentration was determined at 260nm (Type A oligomers: AQ1-C3-seq (Table 1, entry 4), AQ1-C3-HEG-seq (Table 1, entry 5), AQ-1-C3-HEG2-seq (Table 1, entry 6),
30 AQ2-C3-seq (Table 1, entry 10) and BP-C3-seq (Example 10, oligo 1). Type B oligomers: AQ1-C3-seq (Table 1, entry 1), AQ1-C3-HEG-seq (Table 1, entry 2), AQ1-C3-HEG2-seq (Table 1, entry 3), AQ2-C3-seq (Table 1, entry 11) and BP-C3-seq (Example 10, oligo 2). Desired oligo concentrations were diluted in 0.2 M NaCl (12.5 μM) and further 5 fold dilutions were made (2.5, 0.5, 0.1, 0.02, 0.004, 0.0008 μM) in 0.2 M NaCl. For each
35 oligomer 100 μL of each concentration was dispensed per microtiter well. The


immobilisation procedure was performed by irradiation with soft UV-light for 15 minutes 10 cm above the microtiter plate (MTP). The MTP was then washed with with 3x300 μ L/well demineralised water.

- 5 2 μ M complementary biotinylated oligonucleotides (complementary to type A oligomers: 5'-biotin-CATGGTCATAGCTGTT-3' and complementary to type B oligomers: 5'-biotin-ACTGGCCGTCGTTTTAC-3') were hybridised to the immobilised oligonucleotides in 100 μ L/well 2xSSCT (30 mM citrate, 0.3 M NaCl, pH 7.0, 0.05% (v/v) Tween 20) for 60 minutes at 37°C. The MTP was washed with 3x300 μ L/well phosphate buffered saline (1xPBST, 10 0.15 M , pH 7.2, 0.05% (v/v) Tween 20) and incubated with 100 μ L/well 1 μ g/mL streptavidin conjugated with horse radish peroxidase diluted in 1xPBST at 37°C for 15 minutes. After washing with 3x300 μ L/well 1xPBST a simple calorimetric endpoint measurement was obtained after addition of 0.66 mg ortho-phenylenediamine, 0.1M citrate-phosphate buffer, pH 5.0, 0.012% H_2O_2 (100 μ L/well). The reaction was stopped 90 sec. after adding 15 100 μ L/well 0.5M H_2SO_4 and the absorbency was measured in a microtiter plate reader at 492nm.

As shown in Figures 6 and 7 both the AQ oligomers and the BP oligomers yield a clearly concentration dependent signal. When using a non-complementary sequence no signal 20 could be detected. We conclude that both AQ and BP oligomers can be covalently attached to a solid surface by irradiation with similar efficiencies and that oligomers attached in this way are able to hybridise to their complementary target DNA oligomers.

CLAIMS

1. A phosphoramidite reagent of the formula I




- 5 wherein Y and Y' each independently are selected from optionally substituted C₁₋₆-alkyl or Y and Y' together with the nitrogen to which they are bonded form a non-aromatic N-heterocyclic ring; W is selected from O and S; X is selected from optionally substituted C₁₋₆-alkyl and optionally substituted benzyl; R^N is selected from hydrogen C₁₋₄-alkyl, optionally substituted benzyl, optionally substituted quinones, and nucleosides; and Q is
- 10 selected from optionally substituted quinones and optionally substituted photoreactive ketones.
2. A reagent according to claim 1, wherein R^N is hydrogen.
- 15 3. A reagent according to any of the preceding claims, wherein Q is a quinone or an optionally substituted benzophenone.
4. A reagent according to claim 3, wherein the quinone is anthraquinone.
- 20 5. A reagent according to claim 3, wherein the quinone is phenanthrenequinone.
6. A reagent according to claim 3, wherein Q is benzophenone.
7. A reagent according to any of the preceding claims, wherein Y and Y' are selected from
- 25 ethyl and isopropyl, in particular isopropyl.
8. A reagent according to claim 7, wherein Y and Y' both are isopropyl.
9. A reagent according to any of claims 1-6, wherein Y and Y' together with the nitrogen to
- 30 which they are bonded form a morpholino ring.


10. A reagent according to any of the preceding claims, wherein X designates 2-cyanoethyl and W designates O.

11. A reagent according to claim 1, which is


5



12. A reagent according to claim 1, which is



13. An oligomer comprising the following fragment:



10 wherein R^N is selected from hydrogen, C_{1-4} -alkyl, optionally substituted benzyl, optionally substituted quinones, and nucleosides; Q is selected from optionally substituted quinones and optionally substituted photoreactive ketones; W and W' are independently selected from O and S; and V is selected from optionally substituted C_{1-6} -alkyl, optionally substituted benzyl, hydrogen, Li^+ , K^+ , Na^+ , and NH_4^+ .

15


14. An oligomer according to claim 13, wherein R^N is hydrogen and Q is selected from anthraquinone and optionally substituted benzophenone.

15. An oligomer according to claim 13, wherein R^N is hydrogen and Q is phenanthrenequinone.

16. An oligomer according to claim 13, wherein R^N is hydrogen and Q is benzophenone.

5


17. A phosphoramidite reagent of the formula II



wherein Y and Y' each independently are selected from optionally substituted C₁₋₆-alkyl or Y and Y' together with the nitrogen to which they are bonded form a non-aromatic N-

10 heterocyclic ring; X is selected from optionally substituted C₁₋₆-alkyl and optionally substituted benzyl; W is selected from O and S; Q is selected from optionally substituted quinones and optionally substituted photoreactive ketones; n is an integer from 1 to 10; and m is 0 or 1.

15 18. An oligomer comprising the following fragment:



wherein Q, W, W', V, n and m are as defined in claim 16.

19. An oligomer according to claim 18, wherein Q is anthraquinone, m is 0 and n is 1.


20 20. An oligomer according to claim 18, wherein Q is an optionally substituted benzophenone, m is 0 and n is 1.

21. An oligomer according to claim 18, wherein Q is phenanthrenequinone, m is 0 and n is 1.

25

22. An oligomer according to claim 18, wherein Q is benzophenone, m is 0 and n is 1.

1/7



a) 3-amino-1-propanol, BOP, Et₃N, DMF. b) *N,N*-diisopropylphosphoramido-chloridite, CH₂Cl₂, DIPEA. c) *N,N,N',N'*-tetraisopropylphosphorodiamidite, tetrazole, CH₂Cl₂, CH₃CN.

Fig. 1

Fig. 1

SUBSTITUTE SHEET (RULE 26)

2/7





Fig. 2

Fig. 2

3/7

3



a) 3-amino-1-propanol, BOP, Et₃N, DMF. b) 2-cyanoethyl *N,N,N',N'*-tetraisopropylphosphorodiamidite, tetrazole, CH₂Cl₂, CH₃CN

Fig. 3

Fig. 3




Fig. 4

Fig. 4

5/7




Figure 5A




Figure 5B

Fig. 5

Fig. 5

6/7




Fig. 6

Fig. 6

7/7




Fig. 7

Fig. 7

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 00/00375

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07F 9/24, C07H 21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07F, C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPODOC, WPI, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9943688 A1 (SURMODICS, INC.), 2 Sept 1999 (02.09.99) --	1-22
A	US 5292873 A (STEVEN E. ROKITA ET AL), 8 March 1994 (08.03.94) --	1-22
A	US 5650399 A (STEVEN E. ROKITA ET AL), 22 July 1997 (22.07.97) --	1-22
A	WO 9012802 A1 (THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE), 1 November 1990 (01.11.90) --	1-22



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 October 2000

Date of mailing of the international search report

09. 11. 2000

Name and mailing address of the ISA/
European Patent Office

Authorized officer

EVA JOHANSSON/EÖ

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 00/00375

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0359225 A2 (E.I. DU PONT DE NEMOURS AND COMPANY), 21 March 1990 (21.03.90) ----- -- -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

03/10/00

International application No.

PCT/DK 00/00375

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9943688	A1	02/09/99	AU	2872999 A	15/09/99
US	5292873	A	08/03/94	NONE		
US	5650399	A	22/07/97	NONE		
WO	9012802	A1	01/11/90	AU	633911 B	11/02/93
				AU	5526390 A	16/11/90
				CA	2049361 A	19/10/90
				EP	0469042 A	05/02/92
				JP	4500679 T	06/02/92
EP	0359225	A2	21/03/90	CA	1338597 A	17/09/96
				DE	68925446 D,T	04/07/96
				DK	453689 A	16/03/90
				JP	2174792 A	06/07/90
				US	4997928 A	05/03/91
				US	5262536 A	16/11/93